Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the overall safety and tolerability profile of linagliptin was similar to placebo, with no significant difference in hypoglycaemia.
Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label Type 2 Diabetes (T2D). Show all posts
Showing posts with label Type 2 Diabetes (T2D). Show all posts
Subscribe to:
Posts (Atom)